Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer

North Eastern German Society of Gynaecological Oncology129 enrolled

Overview

The combination of paclitaxel and carboplatin in a three weeks schedule has emerged as the current standard approach for the adjuvant treatment of ovarian cancer. Based on a phase I study now a multi-center phase II-trial was conducted.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

129

Conditions

Ovarian Cancer

Interventions

PaclitaxelDRUG

CarboplatinDRUG

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * histologically-confirmed epithelial ovarian cancer of FIGO stage IIB - IV * life expectancy of more than three months * ECOG performance status less than 3 * laboratory parameters within the normal range, including a glomerular filtration rate (GFR) greater than 60 ml/min, serum creatinine levels below 1.6 mg/dl, liver transaminases less than two times the normal levels, bilirubin concentrations below 1.5 mg/dl, adequate bone marrow function as indicated by a neutrophil count greater than 1,500/µl, and a platelet count greater than 100,000/µl. * written informed consent Exclusion Criteria: * suffering from secondary malignancy or underlying serious, uncontrolled concurrent medical or psychiatric disease * radiotherapy within 4 weeks for study entry

Locations (1)

Charité Campus Virchow-Klinikum

Berlin, Germany

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.